Invention Grant
- Patent Title: Osteoclast inhibitors for joint conditions
-
Application No.: US15716334Application Date: 2017-09-26
-
Publication No.: US09956234B2Publication Date: 2018-05-01
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Maschoff Brennan Laycock Gilmore
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/675
- IPC: A61K31/675 ; A61K31/663 ; A61K9/00 ; A61K31/573 ; A61K45/06 ; A61K9/20
Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as joint pain.
Public/Granted literature
- US20180015110A1 OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS Public/Granted day:2018-01-18
Information query
